Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136


Breast leptomeningeal disease: a review of current practices and updates on management.

Figura NB, Rizk VT, Armaghani AJ, Arrington JA, Etame AB, Han HS, Czerniecki BJ, Forsyth PA, Ahmed KA.

Breast Cancer Res Treat. 2019 Jun 17. doi: 10.1007/s10549-019-05317-6. [Epub ahead of print] Review.


Immunotherapy in breast cancer: Current status and future directions.

Basu A, Ramamoorthi G, Jia Y, Faughn J, Wiener D, Awshah S, Kodumudi K, Czerniecki BJ.

Adv Cancer Res. 2019;143:295-349. doi: 10.1016/bs.acr.2019.03.006. Epub 2019 May 2.


Vaccine Therapies for Breast Cancer.

Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ.

Surg Oncol Clin N Am. 2019 Jul;28(3):353-367. doi: 10.1016/j.soc.2019.02.004. Epub 2019 Apr 5. Review.


Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.

Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA.

Breast Cancer Res Treat. 2019 Jun;175(3):781-788. doi: 10.1007/s10549-019-05170-7. Epub 2019 Mar 11.


Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib.

Showalter LE, Oechsle C, Ghimirey N, Steele C, Czerniecki BJ, Koski GK.

PLoS One. 2019 Jan 18;14(1):e0210209. doi: 10.1371/journal.pone.0210209. eCollection 2019.


Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer.

De La Cruz LM, Czerniecki BJ.

Ann Surg Oncol. 2018 Oct;25(10):2852-2857. doi: 10.1245/s10434-018-6620-5. Epub 2018 Jul 16. Review.


Personalizing Radiation Treatment Delivery in the Management of Breast Cancer.

Ahmed KA, Grass GD, Orman AG, Liveringhouse C, Montejo ME, Soliman HH, Han HS, Czerniecki BJ, Torres-Roca JF, Diaz R.

Int J Breast Cancer. 2018 Jun 10;2018:6729802. doi: 10.1155/2018/6729802. eCollection 2018. Review.


Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy.

Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson AARA, Czerniecki BJ, Harrison LB, Moros EG, Enderling H.

Sci Rep. 2018 Jun 21;8(1):9474. doi: 10.1038/s41598-018-27718-1.


Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.

Rosemblit C, Datta J, Lowenfeld L, Xu S, Basu A, Kodumudi K, Wiener D, Czerniecki BJ.

Oncotarget. 2018 May 1;9(33):23058-23077. doi: 10.18632/oncotarget.25208. eCollection 2018 May 1.


Histological immune response patterns in sentinel lymph nodes involved by metastatic melanoma and prognostic significance.

Abbott J, Buckley M, Taylor LA, Xu G, Karakousis G, Czerniecki BJ, Gimotty PA, Zhang PJ.

J Cutan Pathol. 2018 Jun;45(6):377-386. doi: 10.1111/cup.13127. Epub 2018 Mar 23.


Occult Breast Carcinoma Presenting as Scalp Metastasis.

Costa RLB, Costa-Filho RB, Rosa M, Czerniecki BJ.

Case Rep Oncol. 2017 Nov 10;10(3):992-997. doi: 10.1159/000484346. eCollection 2017 Sep-Dec.


Transected thin melanoma: Implications for sentinel lymph node staging.

Herbert G, Karakousis GC, Bartlett EK, Zaheer S, Graham D, Czerniecki BJ, Fraker DL, Ariyan C, Coit DG, Brady MS.

J Surg Oncol. 2018 Mar;117(4):567-571. doi: 10.1002/jso.24930. Epub 2017 Nov 30.


The impact of preoperative magnetic resonance imaging and lumpectomy cavity shavings on re-excision rate in pure ductal carcinoma in situ-A single institution's experience.

So A, De La Cruz LM, Williams AD, Bahng J, Liao G, McDonald ES, Fisher CS, Czerniecki BJ, Sataloff D, Tchou J.

J Surg Oncol. 2018 Mar;117(4):558-566. doi: 10.1002/jso.24890. Epub 2017 Nov 11.


The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives.

Costa RLB, Soliman H, Czerniecki BJ.

Cancer Treat Rev. 2017 Dec;61:107-115. doi: 10.1016/j.ctrv.2017.10.005. Epub 2017 Oct 28. Review.


Oncoplastic Surgery: Keeping It Simple With 5 Essential Volume Displacement Techniques for Breast Conservation in a Patient With Moderate- to Large-Sized Breasts.

Chatterjee A, Dayicioglu D, Khakpour N, Czerniecki BJ.

Cancer Control. 2017 Oct-Dec;24(4):1073274817729043. doi: 10.1177/1073274817729043. Review.


Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.


Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ.

Nocera NF, Lee MC, Czerniecki BJ.

Future Oncol. 2017 Jul;13(17):1459-1462. doi: 10.2217/fon-2017-0151. Epub 2017 Aug 2. No abstract available.


Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.

Mustafa RE, DeStefano LM, Bahng J, Yoon-Flannery K, Fisher CS, Zhang PJ, Tchou J, Czerniecki BJ, De La Cruz LM.

Ann Surg Oncol. 2017 Oct;24(10):2999-3003. doi: 10.1245/s10434-017-5941-0. Epub 2017 Aug 1.


Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival.

Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H.

Breast Cancer Res. 2017 Jun 30;19(1):75. doi: 10.1186/s13058-017-0870-1.


Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma.

Sinnamon AJ, Neuwirth MG, Bartlett EK, Zaheer S, Etherington MS, Xu X, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC.

J Surg Oncol. 2017 Dec;116(7):848-855. doi: 10.1002/jso.24743. Epub 2017 Jun 26.


Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.

Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, Roses RE, Czerniecki BJ.

Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13.


Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer.

De La Cruz LM, McDonald ES, Mick R, Datta J, Nocera NF, Xu S, Fisher CS, Czerniecki BJ.

Ann Surg Oncol. 2017 Apr;24(4):1057-1063. doi: 10.1245/s10434-016-5651-z. Epub 2016 Nov 8.


Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis.

Karakousis G, Gimotty PA, Bartlett EK, Sim MS, Neuwirth MG, Fraker D, Czerniecki BJ, Faries MB.

Ann Surg Oncol. 2017 Apr;24(4):952-959. doi: 10.1245/s10434-016-5646-9. Epub 2016 Nov 2.


Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.

Nocera NF, Lee MC, De La Cruz LM, Rosemblit C, Czerniecki BJ.

Front Pharmacol. 2016 Oct 6;7:356. eCollection 2016. Review.


Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.

Fracol M, Datta J, Lowenfeld L, Xu S, Zhang PJ, Fisher CS, Czerniecki BJ.

Ann Surg Oncol. 2017 Feb;24(2):407-417. doi: 10.1245/s10434-016-5584-6. Epub 2016 Sep 23.


Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

De La Cruz LM, Nocera NF, Czerniecki BJ.

Immunotherapy. 2016 Oct;8(10):1219-32. doi: 10.2217/imt-2016-0052. Review.


HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.

Ecker BL, Taylor L, Zhang PJ, Furth EE, Ginsberg GG, McMillan MT, Datta J, Czerniecki BJ, Roses RE.

PLoS One. 2016 Aug 25;11(8):e0161781. doi: 10.1371/journal.pone.0161781. eCollection 2016.


Heterodyne frequency-domain multispectral diffuse optical tomography of breast cancer in the parallel-plane transmission geometry.

Ban HY, Schweiger M, Kavuri VC, Cochran JM, Xie L, Busch DR, Katrašnik J, Pathak S, Chung SH, Lee K, Choe R, Czerniecki BJ, Arridge SR, Yodh AG.

Med Phys. 2016 Jul;43(7):4383. doi: 10.1118/1.4953830.


Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review.

De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ, Tchou J, Fisher CS.

Ann Surg Oncol. 2016 Oct;23(10):3247-58. doi: 10.1245/s10434-016-5313-1. Epub 2016 Jun 29. Review.


Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.

Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ.

Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017.


Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.

Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, Lewis DA, DeMichele A, Czerniecki BJ.

JAMA Oncol. 2016 Feb;2(2):242-6. doi: 10.1001/jamaoncol.2015.5482.


DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.

Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.

J Transl Med. 2015 Oct 24;13:335. doi: 10.1186/s12967-015-0698-3.


Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.

Cintolo JA, Datta J, Xu S, Gupta M, Somasundaram R, Czerniecki BJ.

Melanoma Res. 2016 Feb;26(1):1-11. doi: 10.1097/CMR.0000000000000203.


Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E, Hoyt C, Feldman MD, Zhang PJ, Xu S, Koski GK, Czerniecki BJ.

Oncoimmunology. 2015 Apr 1;4(10):e1022301. eCollection 2015 Oct.


Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity.

Bartlett EK, Peters MG, Blair A, Etherington MS, Elder DE, Xu XG, Guerry D, Ming ME, Fraker DL, Czerniecki BJ, Gimotty PA, Karakousis GC.

Ann Surg Oncol. 2016 Jan;23(1):250-6. doi: 10.1245/s10434-015-4766-y. Epub 2015 Jul 28.


Residents' Experience in Breast Cancer Care.

Conway RG, Bartlett EK, Hoffman RL, Czerniecki BJ, Karakousis GC, Kelz RR.

J Surg Educ. 2015 Nov-Dec;72(6):1233-9. doi: 10.1016/j.jsurg.2015.04.028. Epub 2015 Jun 26.


Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ.

Front Immunol. 2015 Jun 2;6:271. doi: 10.3389/fimmu.2015.00271. eCollection 2015. Review.


Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.

Chung SH, Feldman MD, Martinez D, Kim H, Putt ME, Busch DR, Tchou J, Czerniecki BJ, Schnall MD, Rosen MA, DeMichele A, Yodh AG, Choe R.

Breast Cancer Res. 2015 May 27;17:72. doi: 10.1186/s13058-015-0578-z.


Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ.

Breast Cancer Res. 2015 May 23;17:71. doi: 10.1186/s13058-015-0584-1.


CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.

Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell DJ Jr, Czerniecki BJ.

Cancer Immunol Res. 2015 May;3(5):455-63. doi: 10.1158/2326-6066.CIR-14-0208. Epub 2015 Mar 19.


Sentinel lymph node biopsy in breast cancer: a work in progress.

Chatterjee A, Serniak N, Czerniecki BJ.

Cancer J. 2015 Jan-Feb;21(1):7-10. doi: 10.1097/PPO.0000000000000090. Review.


Optimizing dendritic cell-based approaches for cancer immunotherapy.

Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, Czerniecki BJ.

Yale J Biol Med. 2014 Dec 12;87(4):491-518. eCollection 2014 Dec. Review.


Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.

Lam L, Czerniecki BJ, Fitzpatrick E, Xu S, Schuchter L, Xu X, Zhang H.

J Mol Biomark Diagn. 2014 Nov 14;4(3):151.


A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ Jr.

Hum Gene Ther. 2014 Aug;25(8):730-9. doi: 10.1089/hum.2014.006.


Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.

Roses RE, Datta J, Czerniecki BJ.

Radiat Res. 2014 Aug;182(2):211-8. doi: 10.1667/RR13495.1. Epub 2014 Jul 3. Review.


Optically measured microvascular blood flow contrast of malignant breast tumors.

Choe R, Putt ME, Carlile PM, Durduran T, Giammarco JM, Busch DR, Jung KW, Czerniecki BJ, Tchou J, Feldman MD, Mies C, Rosen MA, Schnall MD, DeMichele A, Yodh AG.

PLoS One. 2014 Jun 26;9(6):e99683. doi: 10.1371/journal.pone.0099683. eCollection 2014.


Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy.

Bartlett EK, Gupta M, Datta J, Gimotty PA, Guerry D, Xu X, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2014 Mar;21(3):1016-23. doi: 10.1245/s10434-013-3388-5. Epub 2013 Nov 21.


Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine.

Lee MK 4th, Xu S, Fitzpatrick EH, Sharma A, Graves HL, Czerniecki BJ.

PLoS One. 2013 Nov 11;8(11):e74698. doi: 10.1371/journal.pone.0074698. eCollection 2013.


Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.

Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schuchter L, Xu X, Elder DE, Ming M, Elenitsas R, Guerry D, Kelz RR, Czerniecki BJ, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2014 Feb;21(2):643-9. doi: 10.1245/s10434-013-3313-y. Epub 2013 Oct 12.

Supplemental Content

Loading ...
Support Center